Mice with a targeted deletion of the T-bet gene exhibit spontaneous airway hyperresponsiveness (AHR), airway inflammation, enhanced recovery of T h 2 cytokines from bronchoalveolar lavage fluid, sub-epithelial collagen deposition and myofibroblast transformation. Here we analyze the mechanisms responsible for the chronic airway remodeling observed in these mice. CD41 T cells isolated from the lung of T-bet-deficient mice were spontaneously activated CD44 high CD69
Introduction
Much experimental evidence indicates a causative relationship between an excessive complement of T h 2 cells and the onset of asthma (1) . For example, circumstances that prejudice against T h 1 development, such as an IL-12 defect, lead to the onset of allergic diseases characterized by over-abundant T h 2 cells (2) . Mice lacking the T h 1-specific transcription factor T-bet have profound defects in the development of the T h 1 subset and the production of IFN-c but over-produce T h 2 cytokines (3, 4) . Double staining for T-bet and CD4 in lung sections from control subjects revealed that~50% of CD4+ cells in the airways express T-bet while lungs from patients with asthma displayed decreased numbers of T-bet+ CD4 cells consistent with a shift towards the T h 2 phenotype (5). Mice either heterozygous or homozygous for loss of the T-bet gene exhibited airway hyperresponsiveness (AHR) to methacholine associated with a peri-bronchial and peri-vascular infiltration with eosinophils and lymphocytes (5, 6) . In contrast to other animal models of asthma, this phenotype occurred spontaneously in the absence of any specific antigenic stimulus or immunological challenge. Interestingly, T-bet heterozygous mice, which have only a 50% reduction of T-bet protein, displayed a phenotype very similar to that of mice with a complete absence of T-bet.
Airway remodeling is a complex feature of chronic asthma and is characterized by increased turnover of the cells and extracellular matrix (ECM) composing the epithelialmesenchymal unit. One phenotype of chronic remodeling is fibrosis, which is characterized in humans by increased collagen (CL) type III deposition below the basement membrane in the airways. In addition, in chronic asthma there is myofibroblast transformation of mesenchymal cells surrounding the medium-and small-sized bronchi. While transforming growth factor beta (TGF-b) has been described as the major factor involved in in vitro fibroblast transformation into myofibroblasts through its effect on the acquisition of intermediate filament proteins such as alpha smooth muscle actin (aSMA), much remains to be learned about the relationship between this cytokine and other potent profibrotic cytokines such as IL-13.
IL-13-mediated fibrosis depends on the concomitant induction of IGF-1 and suppression of TGF-b. As opposed to TGF-b1, IL-4 and IL-13 can increase fibrosis but cannot alone induce myofibroblast transformation in vitro (7) (8) (9) (10) (11) (12) .
Lungs from T-bet-deficient mice undergo airway remodeling histologically similar to human asthmatic lungs, a process which is accompanied by increased concentrations of both TGF-b1 and IL-13 in bronchoalveolar lavage fluid (BALF) (5, 13) . Here we investigate the etiology of this chronic airway remodeling. We demonstrate that in T-bet ÿ/ÿ mice, IL-13 derived from hyperactivated memory CD4 cells controls the asthmatic phenotype observed in T-bet deficiency, in part through its control of TGF-b-driven events.
Methods
Allergen sensitization and challenge and blocking antibody administration SV129/C57BL/6/T-bet ÿ/ÿ intercrossed mice (3) (3 months of age) were maintained under specific pathogen-free conditions and received an intra-peritoneal (i.p.) injection of 100 lg ovalbumin peptide (OVA) (Calbiochem, Germany) complexed with alum (Sigma-Aldrich, Taufkirchen, Germany) on days 0 and 7, as previously described (5, 14) . On day 7, groups of mice (n = 6) received aIL-13 antibody (monoclonal anti-mouse IL-13 antibody; R&D Systems, Germany) (10 or 50 lg as indicated) or aIL-4 (100 lg or 1 mg as indicated) (11B11) by i.p. administration. On day 18, 19 mice were anesthetized with avertine (1 mg tribromethanol per ml t-amylalcohol in 2.5% in PBS) before receiving aIL-13 (50 lg per day), aIL-4 (100 lg per day) or aTGF-b1 (50 or 100 lg per day) (R&D Systems) antibodies intra-nasally (i.n.). Control groups (n = 6) received either rat IgG 2bj isotype control antibodies (PharMingen, San Diego, CA, USA) or normal rabbit IgG (R&D Systems). Afterwards, mice were aerosolized with PBS in a chamber connected to an aerosol generator (FMI: Fohr Medical Instruments, Seeheim, Germany). On day 20, airway plethysmography was performed followed by a bronchoalveolar lavage, as described previously (14) . Three experiments were performed for aIL-13, aIL-4 and aTGF-b treatment. At least five mice per group were treated and analyzed.
Assessment of bronchoconstriction by whole body plethysmograph
Bronchoconstriction was evaluated by using a non-invasive whole body plethysmograph (model PLY 3211; Buxco Electronics, Inc., Sharon, CT, USA), as previously described (5, 14) . Briefly, mice were exposed to 0, 50, 100 mg of methacholine (Sigma) for 3 min by using a sonicator linked to the four exposure chambers, and enhanced pause (Penh) responses of different groups of mice (n = 6 mice per group) in the following 5 min were measured. Data are reported as mean value of 30 values of Penh [mean values (Penh) 6 SEM] taken every 10 s (5 min) after administration of methacholine.
Assessment of AHR and transpulmonary resistance
To assess AHR, we used a whole body plethysmograph. In this system, an esophageal cannula-water coupled to the pressure transducer-is inserted into anesthetized (pentobarbital), spontaneously breathing mice. The mice are ventilated through a ventilator (Mouse Ventilator, Ugo Basile) with the inlet and outlet of the ventilator connected to the distal end of a previously inserted tracheal cannula. Under these conditions, the transpulmonary pressure (tracheal-esophageal) is monitored. The computed mechanical parameters are the lung resistance (RI) and the lung compliance. In our system, these two parameters are measured with a Resistance/ Compliance Isovolumetric analyzer (Buxco Electronics, Inc.) by using a ByoSystem XA software. This analyzer monitors the two inputs flow and pressure from unconscious animals, as well as ventilatory parameters and mechanical parameters on every breath. The resistance parameter is calculated using the common isovolumetric method. In the isovolumetric method, the flow changes are measured by finding the difference between the inspiratory flow and expiratory flow measured at a certain volume. The pressure changes are measured in the same way. Airflow is calibrated by using the Int-Zero calibration method (also used for the Penh measurements) with 1-ml air injection. The pressure is calibrated using a water manometer attached to the transducer in accordance with the two-point reading method. Both calibrations were performed according to the manufacturer's instructions (Buxco, Electronics, Inc., BioSystem XA for window). At the beginning of the experiment, different doses of methacholine were instilled intra-tracheally by placing 10 ll of the chosen methacholine concentrations in the in-line aerosol system connected to the plethysmograph.
Isolation and analysis of lung CD4+ T cells
Lung pieces were placed in DMEM (GIBCO) and incubated at 37°C for 1 h in Dulbecco's PBS containing 300 U ml ÿ1 of collagenase type II (Worthington Biochemical Corporation, Lakewood, NJ, USA) and 0.001% DNase (Roche Diagnostics, Heidelberg, Germany). The suspension was then filtered through a 70-lm nucleopore filter (Nunc). After centrifugation, the cell pellet was washed in MACS buffer (PBS/EDTA with 3% FCS; BioWhittaker Europe, Cambrex Company, Verviers, Belgium) followed by incubation with anti-mouse CD4 antibodies bound to beads (10 7 Dynabeads CD4-L3T4 ml ÿ1 ; 25 ll beads for 2.5 3 10 6 cells) for 20 min at 4°C under shaking conditions. Lung CD4+ cells were isolated by positive magnetic selection in accordance with the manufacturer's instructions. aCD4 beads were detached by using mouse CD4 DETACHaBEAD (Dynal, Hamburg, Germany). CD4+ cells were cultured with soluble aCD28 and plate-bound aCD3 antibodies (CD3, clone 145-2C11, 5 lg ml ÿ1 ; CD28, clone 37.51, 2 lg ml ÿ1 ; PharMingen) overnight at a density of 10 6 cells ml ÿ1 . Supernatants were analyzed for cytokine production by ELISA as described below. The cell pellet was processed for RNA extraction.
To analyze lung CD4 T cell activation, naive, untreated T-betdeficient and wild-type (wt) mice on a SV129/B6 genetic background were analyzed. CD4+ T cells were directly purified from isolated lung cell suspensions using aCD4+ mouse bead-conjugated mAbs (Miltenyi, Bergisch Gladbach, Germany) in a multiparameter magnetic sorter system (MACS, Miltenyi). The resulting CD4+ cells (purity 97%) were further stained with an anti-mouse CD4-PE-conjugated antibody (PharMingen), with aCD69-FITC-conjugated and anti-mouse CD44-CyChrome-conjugated antibodies for 30 min at 4°C, washed twice in PBS and then analyzed by FACS analysis with a FACSCalibur (BD PharMingen).
Isolation and functional analysis of lung CD4+CD25+ cells
Isolation of CD4+CD25+ T regulatory cells (Treg) was performed after bead detachment of isolated CD4+ T lung cells derived either from untreated wt or T-bet ÿ/ÿ mice (Fig.  1A) on a SV129/B6 genetic background. In additional experiments (Fig. 6A ), CD4+CD25+Tregs were isolated from T-bet ÿ/ÿ mice that had been sensitized i.p. with OVA as described above and challenged with PBS and in vivo treated either with normal rabbit serum or aTGF-b antibodies i.n. The method of isolation of lung CD4+CD25+ cells is described below.
After bead detachment, enriched CD4+ lung cells derived from either untreated wt or T-bet ÿ/ÿ SV129/B6 mice were stained with CD25-PE antibody followed by incubation with anti-PE beads and immunomagnetic separation (CD25 Microbead Kit mouse, Miltenyi Biotech). Lung CD4+CD25+ (10 5 (Fig. 6B) . Purity of CD4+CD25+ T cell populations was assessed by measuring Foxp3 transcripts.
Lung fibroblast cell culture
Lung fibroblasts were grown from lung cell suspensions from untreated mice (3 months of age) immediately after enzymatic digestion or from the CD4ÿÿ fraction after CD4++ cell isolation as described above. Lung cells were then seeded at a density of 10 6 cells ml ÿ1 in 24-well plates and cultured in DMEM with high glucose, glutamine, pyruvate, 1% penicillin/ ptreptomycin and amphotericin B (250 mg L ÿ1 ) (Biochrom AG, Berlin, Germany) and 10% FCS overnight. The day after, supernatants with dead cells were removed and the adherent cells further cultured to semi-confluence. Semi-confluence typically occurred after 5 days when fibroblasts were isolated from T-bet ÿ/ÿ lung and after 2 weeks from wt lung. On day 5, cells were washed in PBS and then cultured in DMEM medium minus amphotericin B and the serum concentration was reduced to 0.4% overnight. Supernatants were collected the day after (day 6) and analyzed for TGF-b production by ELISA (Fig. 7H ) and fibroblast cultures frozen for subsequent immunocytochemical studies.
Immunohistochemistry
Fibroblasts and myofibroblasts were immunostained directly in culture wells as previously described with some modifications (18) . Briefly, fibroblasts were fixed in 2% PFA, permeabilized with permeabilization buffer (0.3% Triton X-100 in PBS) and washed twice in Tris-buffered saline (TBS) buffer (0.05 M Tris-hydrochloride). After 1 h incubation in blocking buffer (3% BSA, 0.05% Tween 20 in TBS), the rabbit polyclonal antivimentin antibody (Santa Cruz Biotechnology, Heidelberg, Germany) was applied (1: 100) in antibody diluent (Dako, Carpinteria, CA, USA) and incubated overnight at 4°C. The following day a goat anti-rabbit biotinylated antibody (Vector Laboratories, Burlingame, OA, USA; 1: 200 in blocking buffer) was applied followed by incubation with Cy3-streptavidin. Detection of aSMA+ cells was performed after further incubation with monoclonal aSMA (1: 100; Sigma) followed by incubation with a biotinylated horse anti-mouse antibody followed by Cy3-streptavidin (1: 500 in PBS). SMAD3 and SMAD7 proteins were detected by immunofluorescence using anti-SMAD3 and anti-SMAD7 rabbit polyclonal antibodies (Santa Cruz Biotechnology) followed by incubation with a biotinylated goat anti-rabbit antibody (Vector Laboratories; 1: 200 in blocking buffer) followed by Cy2-streptavidin green fluorochrome (1: 500 in PBS) (Fig. 6C ).
ELISA
Mouse IL-4, IL-5, IFN-c and IL-10 were detected using a specific sandwich ELISA (OptEIA TM , BD PharMingen). Murine IL-13 was detected using an ELISA kit (R&D Systems). TGF-b analysis was performed by using purified rat antimouse, human, pig TGF-b1 as capture antibody (PharMingen, Heidelberg, Germany) and biotinylated rat anti-mouse, human, pig TGF-b1 (PharMingen) polyclonal antibody. Recombinant TGF-b was purchased from R&D Systems. To activate latent TGF-b, 200-ll samples was pre-treated with 10 ll of 1 N HCl for 30 min at 37°C. Samples were then neutralized by adding 10 ll of 1 N NaOH.
Protein extraction, western blot analysis and immunoprecipitation
Tissue proteins were extracted as previously described from naive untreated mice (14) . Briefly, tissue was homogenized in PBS and protein extracted in the presence of protease inhibitors. After boiling for 2 min, proteins were separated by 10 or 15% SDS-PAGE, transferred to nitrocellulose membranes washed briefly in PBS and incubated in blocking solution (5% milk in PBS/0.05% Tween 20) for 1 h at room temperature, and subsequently exposed to 1 lg ml ÿ1 of antibodies against b-actin, SMAD3 (Santa Cruz Biotechnology) or aSMA and anti-vimentin (Sigma), in blocking solution. Specific binding was visualized with the ECL western blotting detection system according to the manufacturer's instruction after 1 h incubation with the corresponding secondary HPRconjugated antibody (1: 2000 in blocking solution) (Amersham Pharmacia Biotech, Germany).
For immunoprecipitation, 250 lg total lung proteins was precleared with 1 lg of appropriate IgG according to the primary antibody and 20 ll A/G plus agarose (Santa Cruz Biotechnology) for 30 min at 4°C. After centrifugation at 2500 r.p.m. for 5 min, supernatant was collected and incubated with 2 lg primary antibody (SMAD3) for 1 h at 4°C followed by addition of 20 ll of A/G plus agarose. The immunoprecipitation was completed by incubation at 4°C overnight under rotating conditions. The next day, the pellet was washed four times with PBS and re-suspended in 50 ll PBS. Western blots were performed as described above with one-third of immunoprecipitated protein, blotted in a nitrocellulose membrane and incubated with anti-phosphoserine residues of SMAD2 and 3 (Upstate, Milton Keynes, UK).
Statistical analysis
Differences were evaluated for significance (P < 0.05) by the Student's two-tailed t-test for independent events (Excel, PC). Data are given as mean values 6 SEM. 
Results

Isolation of functionally intact lung CD4+CD25+ Tregs but increased numbers of activated/memory CD4+ T cells from T-bet ÿ/ÿ mice
We previously reported that T-bet ÿ/ÿ mice, without allergen challenge, develop hallmark features of asthma with airway inflammation and hyperresponsiveness. Further, immunodeficient mice reconstituted with OVA-specific T-bet ÿ/ÿ spleen CD4+ cells developed airway inflammation and hyperresponsiveness, demonstrating a direct relationship between CD4+ T cells and the asthma phenotype (5). Recent reports have suggested a role for CD25+CD4+ regulatory T cells in inhibiting asthma. Patients with mutations in the transcription factor Foxp3 and hence deficiencies in CD4+CD25+ Tregs (IPEX) present with severe eczema, elevated IgE, eosinophilia and food allergy (19) . However, we have previously reported the presence of an increased rather than a decreased number of Tregs in the absence of T-bet in an adoptive transfer model of inflammatory bowel disease (20) . Nevertheless, we asked whether T-bet ÿ/ÿ mice develop asthma due to a defect in Treg function. CD4+CD25+ and CD4+CD25ÿ cells were isolated directly from the lungs of wt and T-bet ÿ/ÿ untreated mice. Lung CD4+CD25ÿ cells were then labeled with CFSE and co-incubated either with CD4+CD25+ or CD4+CD25ÿ lung T cells in a 1: 1 ratio. Figure 1(A and B) shows that T-bet ÿ/ÿ CD4+CD25+ cells inhibited CD4+CD25ÿ cell proliferation as effectively as did wt CD4+CD25+ T cells, indicating that T-bet ÿ/ÿ mice develop functionally intact immunosuppressive CD4+CD25+ cells in the lung. We conclude that the asthmatic phenotype we observe cannot be accounted for by an impairment in CD4+CD25+ Tregs in the absence of T-bet. In addition, very recent data suggest that freshly isolated CD4+CD25+ cells are not able to suppress T h 2 cells but require pre-activation with co-stimulatory signals in vitro to suppress proliferation and induce Foxp3 in T h 2 cells (21) .
We therefore tested whether conventional lung CD4+ cells might be spontaneously activated in the absence of T-bet. Indeed, lung CD4+ T cells isolated from T-bet ÿ/ÿ untreated mice contained a higher percentage of cells with an 
IL-13 directs asthma in T-bet
ÿ/ÿ mice 997 activated/memory phenotype as compared with littermate controls. As shown in Fig. 1 (Fig. 1C, right panel) and co-stimulatory activation through aCD28 antibodies had no influence on these activation parameters (data not shown). Furthermore, both the percentage and number of activated/memory cells were increased in the T-bet ÿ/ÿ lung CD4+CD25ÿ cell compartment as compared with wt. The efficiency of isolation and separation of the two populations was confirmed by the presence of Foxp3 transcripts in the CD4+CD25+ but not CD4+CD25ÿ populations (Fig. 1D) . We conclude that in the absence of T-bet the ratio of activated/memory to naive lung CD4 T cells is greatly increased relative to what is observed in wt mice.
Lung CD4+ T cells from T-bet
ÿ/ÿ mice release increased T h 2 cytokines T-bet controls T h 1 differentiation in part through direct transcriptional activation of the IFN-c gene and up-regulation of IL-12Rb2 chain expression (22) (23) (24) (25) (26) (27) . An equally important function of T-bet resides in its ability to repress T h 2 cytokine gene expression by a mechanism independent of IFN-cR signaling (22) . We previously reported that T-bet ÿ/ÿ mice spontaneously release increased amounts of T h 2 cytokines in the periphery and in the airways as measured in BALF (5). We wished to establish the cytokine profile of CD4+ Tcells isolated directly from the lung. As shown by ELISA in Fig. 2 T cells was further increased (Fig. 2A) . Of particular interest was the over-production of IL-13 by T-bet ÿ/ÿ as compared with wt lung CD4 cells. Indeed, after OVA sensitization, levels of IL-13 (D) increased further, reaching~6 ng ml ÿ1 , a very high value.
Local blockade of IL-4 and IL-13 ameliorates airway inflammation in T-bet ÿ/ÿ mice A hallmark feature of asthma is airway inflammation, characterized by peri-vascular and peri-bronchial infiltration of the airways with eosinophils and lymphocytes. We previously reported that T-bet ÿ/ÿ mice, in the absence of any immunological challenge, had increased infiltration of eosinophils and lymphocytes in airways as assessed by histologic analysis. To more precisely quantitate the cellular infiltrate, we examined BALF of untreated wt and T-bet ÿ/ÿ mice. T-bet ÿ/ÿ mice had increased overall cell numbers in BALF (total cell number 3 T-bet ÿ/ÿ 458.01 6 209.1, P = 0.049), confirming the previous histological analysis. Both IL-4 and IL-13 contribute to the asthmatic phenotype. To ask whether these cytokines, whose levels were increased in T-bet ÿ/ÿ lung, were involved in the asthmatic phenotype, we neutralized IL-13 and IL-4 by i.p. and i.n. delivery of specific antibodies. As shown in Fig. 3A , i.n. blockade of either IL-13 (50 lg i.p. on day 7 and 50 lg per day for 2 days i.n. on days 18 and 19) or IL-4 (1 mg i.p. on day 7 and 100 lg per day i.n. on days 18 and 19), in OVA-sensitized mice, suppressed the number of eosinophils in the BALF as compared with control IgG (100 lg i.p. and 100 lg per day on days 18 and 19). IL-5 is the major growth and differentiating factor for eosinophils. Consistent with the reduction in eosinophil number, aIL-13 treatment led to decreased IL-5 production in the BALF of treated mice (Fig. 3B) . We also examined whether IL-13 blockade affected the production of cytokines specifically from CD4 T cells. Indeed, treatment with IL-13 antibody reduced IL-5 production from CD4 T cells (Fig. 3C) . Interestingly, levels of the protective cytokine IFN-c, although low as expected in the absence of T-bet, were increased after treatment with IL-13 antibody, suggesting that non-T-bet-dependent IFN-c production was IL-13 mediated (Fig. 3D ).
Local blockade of IL-13 but not IL-4 or TGF-b ameliorates bronchoconstriction in T-bet ÿ/ÿ mice
We next asked therefore whether local blockade of IL-4 or IL-13 would ameliorate the spontaneous AHR observed in T-bet ÿ/ÿ mice. In an initial series of experiments, we found that i.n.
blockade of IL-4 in OVA-sensitized mice did not lead to a decrease in bronchoconstriction, even when antibodies were given for 2 days i.n. (100 lg per day). Since levels of IL-4 are elevated in T-bet ÿ/ÿ mice in the periphery as well as the lung, we also blocked IL-4 systemically by injecting 1 mg of aIL-4 antibody i.p. during the second OVA sensitization on day 7 before giving aIL-4 i.n. on days 18 and 19 (100 lg per day); however, no effect on bronchoconstriction after methacholine challenge, as compared with IgG control treatment, was observed (Fig. 4A) . Similarly, local blockade of TGF-b i.n. for 2 days on days 18 and 19 (100 lg per day) did not reduce bronchoconstriction in T-bet ÿ/ÿ mice (Fig. 4C) , nor did blockade of TGF-b reduce the release of IL-13 (Fig. 4D) . In contrast, OVA-sensitized T-bet ÿ/ÿ mice that received aIL-13 antibodies i.n. (50 lg per day at days 18 and 19) prior to delivery of aerosol PBS displayed significantly decreased bronchoconstriction as shown in Fig. 4B , where AHR was measured 24 h after the last antibody dose in response to different doses of methacholine. These results demonstrate a direct effect of IL-13 but not IL-4 or TGF-b on the elevated airway bronchoconstriction in T-bet ÿ/ÿ mice.
Local blockade of IL-13 but not IL-4 ameliorates AHR in T-bet ÿ/ÿ mice
We also measured lung resistance (RI) in OVA-sensitized wt and T-bet ÿ/ÿ mice treated i.n. with either aIL-13 or aIL-4 antibodies prior to PBS challenge (OVA/PBS). As shown in Fig. 4F , aIL-13 but not aIL-4 antibody treatment had a protective effect on the development of AHR in T-bet ÿ/ÿ mice. The effect of aIL-4 and aIL-13 antibody treatment on AHR of OVA/PBS-treated wt mice is shown for comparison in Fig. 4(E) . These differences may be explained by our finding that aIL-4, but not aIL-13, treatment led to up-regulation of IFN-c in wt airways while just the reverse was true for T-bet ÿ/ÿ mice where IFN-c was increased by aIL-13 but not by aIL-4 treatment (Fig. 4G) . Taken together, these data indicate a T-bet independent, protective effect likely mediated by IFN-c in the lung of aIL-13-treated mutant mice. 
Activation of TGF-b signal transduction in T-bet
ÿ/ÿ mice Airway remodeling is a complex feature of chronic asthma and is characterized by increased cell turnover and ECM formation composing the epithelial-mesenchymal unit. One phenotype of chronic remodeling is fibrosis, which is characterized in humans by increased CL type III deposition below the basement membrane in the airways. In addition, in chronic asthma there is myofibroblast transformation in mesenchymal cells surrounding the medium-and small-sized bronchi. TGF-b has been described as the major factor involved in in vitro fibroblast transformation into myofibroblasts through acquisition of intermediate filament proteins such as aSMA (13, (28) (29) (30) (31) (32) . Along with increased CL deposition, we have previously found increased transformation of fibroblasts into myofibroblasts in T-bet ÿ/ÿ lungs and increased levels of TGF-b in the BALF of T-bet ÿ/ÿ mice (5). To examine the activation of TGF-b signal transduction in the presence or absence of T-bet in the lung, we immunoprecipitated total lung proteins from untreated wt and T-bet ÿ/ÿ mice with aSMAD3S antibody and immunoblotted them with an antibody directed against the phosphoserine residues of SMAD3S-SMAD2. As shown in Fig. 5(A) , increased phosphorylated SMAD3-SMAD2 complexes were present in proteins immunoprecipitated from the lung of T-bet ÿ/ÿ mice as compared with wt mice, indicating increased activation of TGF-b signal transduction in the former.
aIL-13 treatment inhibits TGF-b production in T-bet
ÿ/ÿ lungs aIL-13 as well as aIL-4 blockade decreased TGF-b production in the BALF as compared with control IgG treatment, although aIL-13 was slightly more potent (Fig. 5B) . However, TGF-b is produced by many cells in the lung, including CD4+ T cells. We therefore analyzed TGF-b release in lung CD4+ T cells isolated from aIL-13-or aIL-4-treated T-bet ÿ/ÿ mice that had been incubated overnight with aCD3 antibody. As shown in Fig. 5(C) , IL-13 (P = 0.0057) but not IL-4 blockade reduced levels of TGF-b from T-bet ÿ/ÿ CD4+ T cells. We conclude that while both IL-13 and IL-4 control TGF-b production in BALF, only IL-13 can control its production in CD4 T cells, at least in the absence of T-bet.
TGF-b blockade does not alter the function of T-bet
ÿ/ÿ CD4+CD25+ lung Tregs or production of T h 2 cytokines from effector T-bet ÿ/ÿ CD4+CD25ÿ cells TGF-b over-production might have consequences for immune system cells as well as for epithelial and mesenchymal cells in the T-bet ÿ/ÿ lung. We analyzed its effect on lung CD4+CD25+ Tregs isolated from T-bet ÿ/ÿ mice treated i.n. with aTGF-b or IgG control antibodies. As shown in Fig. 6A , aTGF-b local treatment in vivo did not change the suppressive function of T-bet ÿ/ÿ CD4+CD25+ Tregs. T-bet ÿ/ÿ lung CD4+CD25+ cells harvested from OVA/PBS/aTGF-b-treated mice inhibited the CFSE-labeled effector cell population as effectively as did lung CD4+CD25+ cells isolated from T-bet ÿ/ÿ aIgG-treated mice (Fig. 6A ). In addition, local blockade of TGF-b in the lung did not change T h 2 cytokine production in lung T h 2 effector cells (Fig. 6B) . The wt lung CD4+CD25+ cell population was Foxp3 positive as found by reverse transcription -PCR, and TGF-b blockade led to down-regulation of Foxp3 expression (Fig. 6B) . Taken together, these data indicate that blockade of IL-13, and hence blockade of TGF-b must ameliorate asthma via mechanisms that involve cells other than or in addition to Tregs. Further, TGF-b does not itself alter cytokines produced by CD4+ cells.
aSMA and vimentin expression is reduced by aIL-13 but not by aIL-4 treatment To understand the mechanism by which IL-13 blockade decreases the asthmatic phenotype of T-bet ÿ/ÿ mice, we analyzed the expression of proteins that characterize chronic airway remodeling in chronic asthma. As shown in Fig. 7A , blockade of IL-13 but not IL-4 led to reduced expression of vimentin, an intermediate intra-cytoplasmic filament expressed in fibroblasts. In addition, IL-13 blockade led to decreased expression of aSMA, the signature protein of myofibroblasts. A direct role of IL-4 on fibrosis has not previously been clearly demonstrated (33) (34) (35) . We conclude that, at least in the setting of T-bet deficiency, IL-13, but not IL-4, controls both fibrosis and remodeling as assessed by vimentin and aSMA expression, respectively (Fig. 7A) . IL-4 IL-13 directs asthma in T-bet ÿ/ÿ mice 1003 may have a secondary role in the remodeling component of asthma induced by T-bet deficiency.
Fibroblasts isolated from T-bet ÿ/ÿ lung survive, proliferate more rapidly and secrete more TGF-b than wt lung fibroblasts Blockade of both IL-13 and IL-4 reduced TGF-b production in BALF and minimally in CD4+ cells suggesting that non-T cells were the source of the TGF-b detected. An attractive candidate cell type is the fibroblast itself. We isolated primary fibroblasts from lungs of T-bet ÿ/ÿ and wt mice. In several independent experiments, fibroblasts isolated from T-bet ÿ/ÿ lung were successfully cultured in vitro especially when IGF (25 ng ml ÿ1 ) was added to the culture medium. By contrast, under these conditions, fibroblasts isolated from wt littermates did not survive or grew slowly, assuming a spindle-shaped form before death (Fig. 7B and D) . In addition, fibroblasts isolated from T-bet ÿ/ÿ mice were resistant to removal by trypsin treatment and could only be recovered by scraping. Microscopically, T-bet ÿ/ÿ fibroblasts were of rounded shape during logarithmic expansion at a time when they expressed vimentin ( Fig. 7C and F) . After reaching semi-confluence, their shape changed to an elongated or expanded form, and the cells acquired alpha smooth muscle filaments (Fig. 7E , G and I). To investigate the mechanism by which T-bet affects fibroblast behavior, semi-confluent fibroblasts were cultured overnight with low serum (0.4% FCS in DMEM) to reach cell synchronization. As shown in Fig. 7H , T-bet ÿ/ÿ lung fibroblasts spontaneously released increased amounts of TGF-b as compared with wt fibroblasts when cultured in the absence of serum (0.4%). T-bet transcripts are not present in lung fibroblasts and no T-bet protein can be detected in lung fibroblasts (data not shown). Thus, we assume that the microenvironment of the T-bet ÿ/ÿ lung, perhaps through autocrine feedback, results in a morphological and functional change in fibroblasts that is retained upon in vitro culture.
Blockade of TGF-b induces SMAD7 and reduces SMAD3 in lung fibroblasts and also diminishes lung fibrosis in vivo in T-bet ÿ/ÿ mice
We next investigated the effect of TGF-b blockade in T-bet ÿ/ÿ lung fibroblasts. As shown in Fig. 8A , local blockade of TGF-b in T-bet ÿ/ÿ lung led to a down-regulation of vimentin, a marker of fibrosis. The expression of the inhibitory SMAD protein, SMAD7, is down-regulated at the basal state in T-bet ÿ/ÿ lung compared with wt littermates consistent with ongoing increased TGF-b signaling in these animals (Fig. 8B) . As expected, anti-TGF-b treatment led to increased SMAD7 and decreased SMAD3 (Fig. 8C ) expression in treated fibroblasts indicating an inhibition of TGF-b signaling in these cells.
Discussion
T h 2 effectors cells develop from naive T cells under the influence of IL-4 produced by T and non-T cells such as IgEactivated mast cells and NK cells (36) . It has been recently demonstrated that NKT cell-deficient mice do not develop AHR following antigen challenge and that this asthmatic phenotype can be reconstituted either by adoptive transfer of NKT cells producing IL-4 and IL-13 or by recombinant IL-13 alone which induces AHR through direct effects on airway smooth muscle cells (36) . Since T-bet ÿ/ÿ mice possess very few NKT cells and those that are present are halted at an immature stage of differentiation (37), it is not likely that they are the origin of the asthmatic phenotype observed. IL-13 shares 30% homology with IL-4 and appears to have certain overlapping biological activities in type II responses. Both cytokines use the IL-4R a-chain and the STAT6-dependent signal transduction pathway. However, despite some overlapping roles, these cytokines do have clearly distinct biological activities. IL-13 is a particularly important asthmainducing cytokine as evidenced by the phenotype of mice that lack or over-express this gene as well as its abundant expression in human asthma (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) . IL-13 over-production leads to airway hyperreactivity, mucus over-production, airway remodeling and most recently has been shown to be required for acidic mammalian chitinase-induced T h 2 inflammation and AHR in a aero-allergen model (1, 11, 12, 41, 44, (51) (52) (53) (54) . Our experiments show that blockade of IL-4 in the lung of T-betdeficient mice affected only the inflammatory component of the asthmatic phenotype present in these mice. By contrast, blockade of IL-13 led to a down-regulation of AHR, inflammation and remodeling (see below).
TGF-b regulates many cellular processes including embryogenesis, inflammation, immune responses and tissue repair. Although TGF-b is released from degranulating platelets at the time of wounding, all of the participating cells can both produce and respond to TGF-b during the course of the healing process. TGF-b stimulates the chemotaxis of fibroblasts, neutrophils and macrophages within the wound bed, alters the pattern of cytokine production by macrophages and induces fibroblasts to secrete ECM proteins such as CLs and fibronectin. TGF-b inhibits the G(1)/S cell cycle transition and alters cytoskeletal organization through multiple parallel downstream signaling pathways. TGF-b signals through transmembrane receptor serine/threonine kinases that activate a family of cytoplasmic proteins called SMADs, which translocate to the nucleus to regulate expression of target genes (55) (56) (57) (58) . Although SMAD2 and SMAD3 are each phosphorylated directly by the TGF-b type I receptor kinase, SMAD3S plays a unique role in the cellular and tissue responses to wounding. Similarly, although both SMAD2 and SMAD3 are phosphorylated directly by the TGF-b and activin type I receptors (ALK5 and ALK4, respectively), selective DNA binding of SMAD3, and not SMAD2, likely directs their distinct cellular targets and different requirements in embryogenesis TGF-b-dependent synthesis of CLs 1, 3, 6 and 7 and tissue inhibitor of metalloproteinases-1 are SMAD3 dependent, as well as the more complex processes of TGF-b-dependent chemotaxis and inhibition of epithelial migration, implicating this pathway in both wound healing and fibrosis (55) (56) (57) (58) (59) (60) . We found evidence for a role of TGF-b signaling in inducing the chronic airway remodeling observed in T-bet ÿ/ÿ lung as evidenced by increased levels of vimentin, decreased expression of SMAD7 and increased expression of SMAD3 in the basal state. However, blockade of TGF-b signaling did not alter the AHR phenotype observed in these mice.
Blockade of IL-4 did not reduce vimentin expression indicating an exclusive function of IL-13 in induction of CL and fibrosis in the setting of T-bet deficiency. These results are consistent with other studies indicating that IL-4 failed to directly stimulate proliferation myofibroblast differentiation, and type I CL production in C57BL/6 murine lung fibroblasts, but was able to do so in CBA/J murine lung fibroblasts, albeit to a lesser extent than that observed with TGF-b, but with comparable intensity relative to the effects of IL-13 (33) . However, lung fibroblasts from both murine strains were equally responsive to TGF-b and PDGF. Several pieces of evidence support the view that IL-4 is not directly responsible for induction of exaggerated ECM deposition but acts primarily as an indirect signal, possibly by regulating the expression of other more potent fibrogenic mediators. This concept is supported by recent studies demonstrating that IL-4 can increase TGF-b production (35) ÿ/-fibroblasts showed reduced in vitro proliferative and profibrotic responses to TGF-b (59).
Mice with a targeted deletion of the T-bet gene spontaneously develop AHR, airway inflammation and increased production of type II cytokines from BALF. They also display airway remodeling as evidenced by increased deposition of CL type III around the airways and by transformation of fibroblasts into myofibroblasts. This constellation of features resembles what is seen in the human disease where the airways of asthmatic patients are occupied by T h 2-type CD4 cells producing IL-13, IL-4 and IL-5 that contribute to lung eosinophilia (IL-5), hyperresponsiveness (IL-13) and fibrosis (IL-4, IL-13). Here we have investigated the mechanisms by which T-bet deficiency leads to an asthmatic phenotype. Our experiments suggest a scenario in which T-bet deficiency results in over-production of IL-13 by T h 2 cells which in turn leads to over-production of IL-5 and of the profibrotic cytokine TGF-b. However, IL-13 acts independently of TGF-b in eliciting the AHR observed in the absence of T-bet. It is interesting that T-box family members have been reported to be responsive to mesoderm/inducing proteins, such as activin, a member of the TGF-b family and basic fibroblast growth factor (15) . We and others have previously reported a negative feedback loop wherein TGF-b itself down-regulates the expression of T-bet which in turn represses the production of TGF-b (16, 20) . We have also recently discovered polymorphisms in the T-bet locus that correlate with the asthmatic phenotype (61); polymorphisms in the IL-13 gene have been identified that correlate with asthma and allergy in a Dutch population (17, 42) and a TGF-b1 polymorphism C509T has been shown to be associated with asthma (62) . One can envision a scenario in the asthmatic lung whereby individuals with genetically lower levels or activity of T-bet (or increased levels or activity of TGFb or IL-13) instigate a negative feedback loop resulting in IL-13-dependent TGF-b over-production and consequent airway remodeling in the setting of other predisposing genetic and environmental stimuli. Increasing the activity of T-bet in the setting of the asthmatic phenotype may prove an effective immunotherapeutic strategy.
